Martín-Torregrosa D, Mansilla-Polo M, Morgado-Carrasco D
Servicio de Dermatología, Hospital Universitario y Politécnico La Fe, IIS La Fe, Valencia, Spain.
Servicio de Dermatología, Hospital de Figueres, Fundació Salut Empordà, Girona, Spain; Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.
Actas Dermosifiliogr. 2025 Jan;116(1):T55-T67. doi: 10.1016/j.ad.2024.10.008. Epub 2024 Oct 9.
Anifrolumab is an inhibitor of the type I interferon receptor subunit 1 (IFNAR1) recently approved for the management of moderate-to-severe systemic lupus erythematosus (SLE). In 2 clinical trials, it has proven effective to treat cutaneous signs. Although anifrolumab has not been indicated for cutaneous lupus erythematosus (CLE), multiple cases and case series (20 publications with a total of 78 patients) have shown good and rapid responses with this drug, both in subacute CLE and discoid lupus erythematosus, as well as in lupus panniculitis and perniosis. Two case reports of dermatomyositis have also experienced clinical improvement with anifrolumab. Clinical trials of this drug are ongoing for subacute CLE and discoid lupus erythematosus, systemic sclerosis, and progressive vitiligo. Its most common adverse effects are respiratory infections and herpes zoster. Anifrolumab may be a well-tolerated alternative in the management of CLE.
阿尼鲁单抗是一种I型干扰素受体亚基1（IFNAR1）抑制剂，最近被批准用于治疗中度至重度系统性红斑狼疮（SLE）。在2项临床试验中，已证明其对治疗皮肤症状有效。尽管阿尼鲁单抗尚未被指明用于治疗皮肤型红斑狼疮（CLE），但多个病例和病例系列（20篇出版物，共78例患者）显示，该药物在亚急性CLE、盘状红斑狼疮以及狼疮性脂膜炎和冻疮中均有良好且快速的反应。2例皮肌炎病例报告也显示使用阿尼鲁单抗后临床症状有所改善。该药物针对亚急性CLE、盘状红斑狼疮、系统性硬化症和进行性白癜风的临床试验正在进行中。其最常见的不良反应是呼吸道感染和带状疱疹。阿尼鲁单抗可能是治疗CLE的一种耐受性良好的替代药物。
